---
title: "Noopept"
slug: "noopept"
type: "compound"
category: "Cognitive"
url: "https://peptidesciencethailand.com/compounds/noopept"
description: "A dipeptide nootropic that modulates BDNF and NGF expression to support memory and neuroprotection. Research background, mechanism, and dosing considerations."
---
# Noopept

*Cycloprolylglycine-Derived Nootropic, Enhancing Neuroplasticity and Cognitive Function*

**Category:** Cognitive  
**Format:** Lyophilized Vial  
**Amount:** 20mg  
**Purity:** >99% (HPLC)

## Overview

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, also known as GVS-111 or Omberacetam) is a synthetic dipeptide-derived nootropic compound originally developed at the Zakusov Research Institute of Pharmacology in Moscow during the 1990s. Structurally, Noopept is a modified cycloprolylglycine dipeptide that shares a pharmacological relationship with the racetam family of compounds, although it is not technically a racetam due to its distinct chemical structure. Its molecular formula is C17H22N2O4 with a molecular weight of 318.37 g/mol, and it is characterized by rapid oral bioavailability and efficient blood-brain barrier penetration.

Noopept has garnered significant research interest due to its potent cognitive-enhancing properties observed at dosages approximately 1,000 times lower than those required for piracetam, the prototypical racetam compound. This extraordinary potency is attributed to its unique pharmacokinetic profile and multi-targeted mechanism of action within the central nervous system. Unlike many nootropic compounds that act on a single neurotransmitter system, Noopept modulates multiple neurochemical pathways simultaneously, producing a broad spectrum of cognitive effects.

The primary mechanism of action of Noopept involves the modulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), two critical neurotrophins that play essential roles in neuronal survival, synaptic plasticity, and cognitive function. Research published in the Journal of Biomedical Science has demonstrated that Noopept administration leads to significant upregulation of both BDNF and NGF mRNA expression in the hippocampus and cerebral cortex, brain regions critically involved in memory formation and higher-order cognitive processing. This neurotrophin-modulating activity is believed to underlie the compound's ability to enhance long-term memory consolidation and retrieval.

Beyond neurotrophin modulation, Noopept interacts with the glutamatergic system, specifically acting as a modulator of AMPA and NMDA receptor activity. AMPA receptors mediate fast excitatory synaptic transmission and play a crucial role in synaptic plasticity mechanisms such as long-term potentiation (LTP), the cellular basis of learning and memory. Research has shown that Noopept enhances AMPA receptor-mediated currents without directly binding to the receptor, instead acting through an allosteric modulatory mechanism that increases the sensitivity of these receptors to glutamate. This ampakine-like activity facilitates more efficient synaptic transmission and strengthens the neural circuits involved in cognitive processing.

Noopept also exerts significant effects on the cholinergic system, enhancing acetylcholine signaling in brain regions associated with memory and attention. Studies have demonstrated increased acetylcholine release in the hippocampus following Noopept administration, contributing to improved memory encoding and retrieval. This cholinergic enhancement occurs without direct acetylcholinesterase inhibition, suggesting an upstream modulatory mechanism that preserves physiological acetylcholine dynamics.

The neuroprotective properties of Noopept have been extensively documented in preclinical research. Studies using models of oxidative stress, excitotoxicity, and amyloid-beta toxicity have shown that Noopept reduces neuronal cell death through multiple protective mechanisms. These include the inhibition of calcium-mediated apoptosis, the suppression of pro-inflammatory cytokine production, and the activation of endogenous antioxidant defense systems. Research published in Experimental Neurology demonstrated that Noopept treatment significantly reduced markers of oxidative stress in hippocampal neurons exposed to hydrogen peroxide, indicating direct cytoprotective activity.

Another important aspect of Noopept's pharmacology is its anti-inflammatory activity within the central nervous system. Neuroinflammation is increasingly recognized as a contributor to cognitive decline and neurodegenerative processes. Noopept has been shown to suppress the activation of microglia, the brain's resident immune cells, and to reduce the production of inflammatory mediators including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). This anti-neuroinflammatory property complements its neurotrophin-modulating effects, creating a synergistic environment that supports both neuronal repair and cognitive enhancement.

Pharmacokinetically, Noopept is rapidly absorbed after oral administration, with peak plasma concentrations reached within 15 to 20 minutes. It crosses the blood-brain barrier efficiently due to its lipophilic dipeptide structure. Once in the brain, Noopept is metabolized to cycloprolylglycine, an endogenous neuropeptide that itself possesses cognitive-enhancing and anxiolytic properties. This bioactive metabolite extends the effective duration of Noopept's cognitive effects beyond the parent compound's relatively short plasma half-life.

Research into Noopept's effects on cognitive function has yielded promising preclinical results. Animal studies have demonstrated improvements in spatial memory, object recognition, passive avoidance learning, and contextual fear conditioning. Electrophysiological studies have confirmed enhanced long-term potentiation in hippocampal slices treated with Noopept, providing a cellular-level explanation for the observed memory enhancements. These findings have positioned Noopept as a compound of considerable interest in the field of cognitive neuroscience and nootropic research.

## Mechanism of Action

### Step 1: Blood-Brain Barrier Penetration

Noopept rapidly crosses the blood-brain barrier due to its lipophilic dipeptide structure, reaching peak brain concentrations within 15-20 minutes of administration and accumulating in hippocampal and cortical regions.

### Step 2: BDNF and NGF Upregulation

Within target neurons, Noopept stimulates the transcription of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA, increasing neurotrophin levels that promote synaptic plasticity and neuronal survival.

### Step 3: AMPA Receptor Modulation

Noopept acts as an allosteric modulator of AMPA receptors, enhancing glutamate-mediated excitatory transmission and facilitating long-term potentiation (LTP), the cellular mechanism underlying memory formation.

### Step 4: Cholinergic Enhancement

The compound increases acetylcholine release in the hippocampus through upstream modulatory mechanisms, improving memory encoding and retrieval without direct acetylcholinesterase inhibition.

### Step 5: Neuroprotective Cascade

Noopept activates endogenous antioxidant defense systems, suppresses microglial-mediated neuroinflammation, and inhibits calcium-mediated apoptosis, protecting neurons from oxidative stress and excitotoxic damage.

## Researched Benefits

### Enhanced Memory and Learning

Preclinical studies demonstrate that Noopept significantly improves both short-term and long-term memory formation through BDNF/NGF upregulation and AMPA receptor modulation. Animal models show improvements in spatial memory, object recognition, and associative learning at doses approximately 1,000 times lower than piracetam.

### Neuroprotective Activity

Noopept exhibits broad-spectrum neuroprotective properties, reducing neuronal cell death caused by oxidative stress, excitotoxicity, and amyloid-beta exposure in preclinical models. These protective effects are mediated through calcium homeostasis regulation and antioxidant enzyme activation.

### Anti-Neuroinflammatory Effects

Research demonstrates that Noopept suppresses microglial activation and reduces pro-inflammatory cytokine production (IL-6, TNF-alpha) within the central nervous system. This anti-neuroinflammatory activity helps preserve cognitive function and supports neuronal health in conditions associated with chronic brain inflammation.

### Anxiolytic Properties

Noopept and its primary metabolite cycloprolylglycine demonstrate anxiolytic effects in preclinical behavioral models without the sedation or cognitive impairment associated with benzodiazepines. This anxiolytic activity is believed to be mediated through modulation of inhibitory neurotransmitter systems.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 10-30mg per day, administered orally or sublingually, typically divided into 2-3 doses |
| Route | Oral or sublingual administration; injectable formulations are also used in research settings |
| Duration | 1.5-3 month cycles |
| Cycle Notes | Standard protocols suggest cycling Noopept for 1.5 to 3 months followed by a 1-month rest period. Some protocols recommend starting at the lower end (10mg/day) and titrating upward based on individual response. |
| Reconstitution | For injectable formulations, reconstitute lyophilized powder with bacteriostatic water according to vial concentration. For oral use, Noopept is typically administered as a measured powder or in capsule form. |

> **Specialist note:** A your specialist will determine the appropriate dosage and route of administration based on individual neurological status, cognitive goals, concurrent medications (particularly those affecting glutamatergic or cholinergic systems), and overall health profile.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 20mg per vial |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111) |
| Molecular Weight | 318.37 g/mol |
| Storage | Store at room temperature (15-25°C) in a dry, dark environment. Reconstituted solutions at 2-8°C. |
| Appearance | White crystalline powder |

## Medical Guidance

Noopept modulates glutamatergic neurotransmission via AMPA and NMDA receptor pathways, which means it can interact with medications that affect excitatory signaling in the brain. Individuals taking anticonvulsants, NMDA receptor antagonists, cholinergic medications, or other nootropic compounds require medical assessment before initiating a Noopept protocol. Individuals with a history of seizure disorders should exercise particular caution.

## Frequently Asked Questions

### What is Noopept and how does it differ from racetams?

Noopept (GVS-111) is a synthetic dipeptide-derived nootropic compound that shares pharmacological similarities with the racetam family but is structurally distinct. It is not a true racetam, as it lacks the 2-pyrrolidone nucleus. Noopept is approximately 1,000 times more potent than piracetam on a per-milligram basis, and it works primarily through BDNF/NGF upregulation, AMPA receptor modulation, and cholinergic enhancement rather than solely through acetylcholine pathways.

### Is Noopept a peptide?

Noopept is a synthetic dipeptide derivative, meaning it is derived from a two-amino-acid peptide backbone (prolylglycine) with additional chemical modifications. While it is not a full-length peptide in the traditional sense, its dipeptide structure classifies it within the broader category of peptide-derived research compounds. Its metabolite, cycloprolylglycine, is an endogenous neuropeptide.

### What cognitive functions has Noopept been studied for?

Preclinical research has investigated Noopept's effects on spatial memory, object recognition, associative learning, attention, and processing speed. Studies published in journals including Experimental Neurology and the Journal of Biomedical Science have demonstrated improvements across multiple cognitive domains in animal models. Its neuroprotective properties have also been studied in models of oxidative stress and amyloid-beta neurotoxicity.

### How quickly does Noopept take effect?

Noopept is rapidly absorbed, reaching peak plasma and brain concentrations within 15-20 minutes of oral administration. Some acute cognitive effects may be observed within this timeframe. However, the neurotrophin-mediated effects (BDNF and NGF upregulation) require consistent administration over days to weeks to fully manifest, as these involve changes in gene expression and protein synthesis.

### Can Noopept be combined with other nootropic compounds?

Research protocols have investigated Noopept in combination with choline sources and other nootropic compounds. Because Noopept enhances cholinergic transmission, co-administration with choline precursors is sometimes studied to support acetylcholine synthesis. Any combination protocol must be designed and monitored by a qualified specialist who can assess potential interactions and appropriate dosing.

## Related Compounds

- /compounds/semax
- /compounds/selank
- /compounds/pe-22-28